Skip to main content

What is the difference between Mvasi and Avastin?

Medically reviewed by Judith Stewart, BPharm. Last updated on April 4, 2025.

Official Answer by Drugs.com

Mvasi (bevacizumab-awwb) is a biosimilar to Avastin (bevacizumab).

Mvasi is not interchangeable with Avastin. The prescriber must write a prescription specifically for Mvasi.

A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Avastin), and has no clinically meaningful differences in terms of safety and effectiveness.

See Biosimilar and Interchangeable Biologics: More Treatment Choices

Mvasi has the same approved indications as Avastin, with the exception of hepatocellular carcinoma.

Avastin Mvasi
Generic Name bevacizumab bevacizumab-awwb
How Supplied
  • Injection: 100 mg/4 mL in single dose vial
  • Injection: 400 mg/16 mL in single dose vial
  • Injection: 100 mg/4 mL in single dose vial
  • Injection: 400 mg/16 mL in single dose vial
Indications
  • metastatic colorectal cancer
  • non-squamous non-small cell lung cancer
  • glioblastoma
  • metastatic renal cell carcinoma
  • cervical cancer
  • epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • hepatocellular carcinoma
  • metastatic colorectal cancer
  • non-squamous non-small cell lung cancer
  • glioblastoma
  • metastatic renal cell carcinoma
  • cervical cancer
  • epithelial ovarian, fallopian tube, or primary peritoneal cancer

Mvasi was approved in 2017 as the first biosimilar to Avastin. A second Avastin biosimilar called Zirabev (bevacizumab-bvzr) was approved in 2019, and a third called Alymsys (bevacizumab-maly) was approved in 2022.

Related questions

Read next

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis.

Continue reading

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. The most recently approved biosimilar is Starjemza (ustekinumab-hmny), an interchangeable biosimilar to Stelara, cleared by the FDA on May 22, 2025.

Continue reading

What are anti-VEGF drugs (VEGF inhibitors)?

Anti-VEGF drugs slow the abnormal growth of blood vessels associated with certain cancers and degenerative eye conditions, such as age-related macular degeneration. Anti-VEGF stands for anti-vascular endothelial growth factor. Continue reading

See also:

Related medical questions

Drug information

Related support groups